Physician profile
Charles E Ferree
NPI 1346268323
$4,411.20
in general payments reported to CMS, 2019-2025
40 companies · $158 in 2025
The $158 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,596 · 2020: $87.72 · 2021: $393 · 2022: $379 · 2023: $915 · 2024: $883 · 2025: $158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,956.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,956.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $526.17 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $474.00 | 2019-2025 | Evenity, Prolia, Otezla |
| Abbvie INC. | $361.98 | 2019-2025 | |
| Lilly USA, LLC | $274.07 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $267.80 | 2019-2024 | Farxiga, Breztri |
| Janssen Pharmaceuticals, INC | $225.05 | 2019-2024 | Xarelto, Spravato |
| Pfizer INC. | $212.94 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $197.98 | 2019-2024 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $164.54 | 2019-2024 | Synjardy, Jardiance, Tradjenta |
| Glaxosmithkline, LLC. | $148.68 | 2019-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Abbott Laboratories | $133.72 | 2023-2025 | Freestyle Libre 3 |
| E.R. Squibb & Sons, L.L.C. | $124.13 | 2022-2024 | Eliquis |
| Amneal Pharmaceuticals LLC | $115.97 | 2019-2023 | Unithroid |
| Merck Sharp & Dohme LLC | $114.15 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Novartis Pharmaceuticals Corporation | $108.31 | 2019-2024 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Ferree listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.